SCHEMBL2863756

SCHEMBL2863756

CCOCOc1ccc(CC)c(-c2ccc(C(=O)CC)cc2C(C)C)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRD5A2 P31213 1/20 0.38
ABCB1 P08183 1/20 0.37
NPC1 O15118 2/20 0.36
NPSR1 Q6W5P4 2/20 0.36
HPGD P15428 1/20 0.36
PARP10 Q53GL7 1/20 0.35
MAPT P10636 3/20 0.35
L3MBTL1 Q9Y468 2/20 0.35
CSNK2A2 P19784 1/20 0.35
CSNK2B P67870 1/20 0.35
CSNK2A1 P68400 1/20 0.35
CSNK2A3 Q8NEV1 1/20 0.35
MEN1 O00255 3/20 0.34
KMT2A Q03164 3/20 0.34
RAB9A P51151 3/20 0.34
ALDH1A1 P00352 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
PLK1 P53350 1/20 0.34
LMNA P02545 1/20 0.34
MAPK1 P28482 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2857757 0.87 SRD5A2 (0.39) SRD5A2ABCB1NPC1HPGDPARP10
SCHEMBL2856534 0.83 VDR (0.42) SRD5A2ABCB1NPC1MAPTMEN1
SCHEMBL2854307 0.80 VDR (0.52) SRD5A2NPC1HPGDMAPTMEN1
SCHEMBL2854311 0.80 RXRA (0.44) ABCB1NPC1HPGDMAPTL3MBTL1
SCHEMBL2861743 0.78 HSP90AB1 (0.39) NPC1HPGDMAPTMEN1KMT2A
SCHEMBL13604875 0.75 VDR (0.45) SRD5A2NPC1PARP10MAPTL3MBTL1
SCHEMBL2855100 0.75 SMN1; SMN2 (0.44) NPC1HPGDMAPTL3MBTL1MEN1
SCHEMBL2856305 0.73 PPARG (0.37) ABCB1NPC1HPGDMAPTMEN1
SCHEMBL2855102 0.71 PPARA (0.37) NPC1NPSR1HPGDMAPTL3MBTL1
SCHEMBL2853384 0.68 RAB9A (0.46) NPC1HPGDPARP10MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1456160-B1 VITAMIN D ANALOGUES GALDERMA RES & DEV (FR) 2010-01-20 EP disclosed
US-6924400-B2 Triaromatic vitamin D analogues GALDERMA RESEARCH & DEVELOPMENT, SNC (FR) 2005-08-02 US disclosed
EP-1456160-A2 VITAMIN D ANALOGUES Galderma Research & Development, S.N.C. (FR) 2004-09-15 EP disclosed
US-20030195259-A1 Triaromatic vitamin D analogues GALDERMA RESEARCH & DEVELOPMENT (FR) 2003-10-16 US disclosed
WO-2003050067-A2 VITAMIN D ANALOGUES GALDERMA RESEARCH & DEVELOPMENT, SNC (FR) 2003-06-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030195259-A1 Triaromatic vitamin D analogues CYP24A1, CYP2R1, VDR SRD5A2 18/4885ABCB1 1960/4885NPC1 1306/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.